U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C18H14Cl2N2
Molecular Weight 329.223
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EBERCONAZOLE

SMILES

ClC1=CC(Cl)=C2C(N3C=CN=C3)C4=CC=CC=C4CCC2=C1

InChI

InChIKey=MPTJIDOGFUQSQH-UHFFFAOYSA-N
InChI=1S/C18H14Cl2N2/c19-14-9-13-6-5-12-3-1-2-4-15(12)18(17(13)16(20)10-14)22-8-7-21-11-22/h1-4,7-11,18H,5-6H2

HIDE SMILES / InChI

Molecular Formula C18H14Cl2N2
Molecular Weight 329.223
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Eberconazole is an antifungal drug with broad antimicrobial spectrum of activity. The drug was developed and approved in Spain (Ebernet 1% cream) for the treatment of tinea. Eberconazole exerts fungicidal or fungistatic activity depending on concentration, being fungicidal at higher concentration and fungistatic at lower concentrations. Eberconazole prevents fungal growth by inhibiting ergosterol synthesis, an essential component of the fungal cytoplasmic membrane leading to structural and functional changes. It prevents the fungal ergosterol synthesis by inhibiting lanosterol 14alpha-demethylase enzyme that is responsible for the formation of 14 alpha-methylsterols (precursor of ergosterols).

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Lanosterol 14-alpha demethylase
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
EBERNET

Approved Use

EBERNET 1% cream is indicated in the cutaneous treatment of the following infections caused by Fungi: Tinea corporis, Tinea cruris and Tinea pedis.

Launch Date

2004
Curative
EBERNET

Approved Use

EBERNET 1% cream is indicated in the cutaneous treatment of the following infections caused by Fungi: Tinea corporis, Tinea cruris and Tinea pedis.

Launch Date

2004
Curative
EBERNET

Approved Use

EBERNET 1% cream is indicated in the cutaneous treatment of the following infections caused by Fungi: Tinea corporis, Tinea cruris and Tinea pedis.

Launch Date

2004
PubMed

PubMed

TitleDatePubMed
[Topical treatment with eberconazole of the experimental guinea pig cutaneous candidosis.].
1999 Mar
Patents

Sample Use Guides

Eberconazole (Ebernet 1% cream) should be applied twice a day for 4 weeks. The cream should be applied in sufficient quantity to cover the lesion and surroundings, and should be distributed with the aid of a light massage.
Route of Administration: Topical
Antifungal activity of eberconazole was tested against 200 strains of dermatophytes. The MIC50 values were 0.06 ug/ml (E. floccosum, M. audouinii, M. canis, M. gypseum, T. ajelloi, T. violaceum), 0.03 ug/ml (M. ferrugineum, M. fulvum, T. balcaneum), 0.25 ug/ml (T. erinacei), 0.125 ug/ml (T. interdigitale, T. mentagrophytes, T. rubrum, T. simii, T. tonsurans).
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:29:11 GMT 2023
Edited
by admin
on Fri Dec 15 15:29:11 GMT 2023
Record UNII
V7O1U41C9B
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
EBERCONAZOLE
INN   WHO-DD  
INN  
Official Name English
Eberconazole [WHO-DD]
Common Name English
eberconazole [INN]
Common Name English
(±)-1-(2,4-DICHLORO-10,11-DIHYDRO-5H-DIBENZO(A,D)CYCLOHEPTEN-5-YL)IMIDAZOLE
Systematic Name English
Classification Tree Code System Code
WHO-VATC QD01AC17
Created by admin on Fri Dec 15 15:29:11 GMT 2023 , Edited by admin on Fri Dec 15 15:29:11 GMT 2023
WHO-ATC D01AC17
Created by admin on Fri Dec 15 15:29:11 GMT 2023 , Edited by admin on Fri Dec 15 15:29:11 GMT 2023
NCI_THESAURUS C514
Created by admin on Fri Dec 15 15:29:11 GMT 2023 , Edited by admin on Fri Dec 15 15:29:11 GMT 2023
Code System Code Type Description
INN
6680
Created by admin on Fri Dec 15 15:29:11 GMT 2023 , Edited by admin on Fri Dec 15 15:29:11 GMT 2023
PRIMARY
SMS_ID
100000080501
Created by admin on Fri Dec 15 15:29:11 GMT 2023 , Edited by admin on Fri Dec 15 15:29:11 GMT 2023
PRIMARY
MESH
C118963
Created by admin on Fri Dec 15 15:29:11 GMT 2023 , Edited by admin on Fri Dec 15 15:29:11 GMT 2023
PRIMARY
FDA UNII
V7O1U41C9B
Created by admin on Fri Dec 15 15:29:11 GMT 2023 , Edited by admin on Fri Dec 15 15:29:11 GMT 2023
PRIMARY
NCI_THESAURUS
C72961
Created by admin on Fri Dec 15 15:29:11 GMT 2023 , Edited by admin on Fri Dec 15 15:29:11 GMT 2023
PRIMARY
WIKIPEDIA
Eberconazole
Created by admin on Fri Dec 15 15:29:11 GMT 2023 , Edited by admin on Fri Dec 15 15:29:11 GMT 2023
PRIMARY
DRUG CENTRAL
978
Created by admin on Fri Dec 15 15:29:11 GMT 2023 , Edited by admin on Fri Dec 15 15:29:11 GMT 2023
PRIMARY
PUBCHEM
72051
Created by admin on Fri Dec 15 15:29:11 GMT 2023 , Edited by admin on Fri Dec 15 15:29:11 GMT 2023
PRIMARY
ChEMBL
CHEMBL558722
Created by admin on Fri Dec 15 15:29:11 GMT 2023 , Edited by admin on Fri Dec 15 15:29:11 GMT 2023
PRIMARY
CAS
128326-82-9
Created by admin on Fri Dec 15 15:29:11 GMT 2023 , Edited by admin on Fri Dec 15 15:29:11 GMT 2023
PRIMARY
EPA CompTox
DTXSID90926104
Created by admin on Fri Dec 15 15:29:11 GMT 2023 , Edited by admin on Fri Dec 15 15:29:11 GMT 2023
PRIMARY
EVMPD
SUB06436MIG
Created by admin on Fri Dec 15 15:29:11 GMT 2023 , Edited by admin on Fri Dec 15 15:29:11 GMT 2023
PRIMARY
DRUG BANK
DB13656
Created by admin on Fri Dec 15 15:29:11 GMT 2023 , Edited by admin on Fri Dec 15 15:29:11 GMT 2023
PRIMARY
CHEBI
82862
Created by admin on Fri Dec 15 15:29:11 GMT 2023 , Edited by admin on Fri Dec 15 15:29:11 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
ENANTIOMER -> RACEMATE
SALT/SOLVATE -> PARENT
ENANTIOMER -> RACEMATE
Related Record Type Details
ACTIVE MOIETY